Venlalic© XL is bioequivalent to Efexor©XL, meaning that you can switch patients without any additional risk or safety concerns. The public assessment report in summary states that the original application for marketing authorisation for Venlalic© XL tablets claims “Essential similarity to Efexor© prolonged release capsules, 75mg and 150mg marketed in Sweden by Pfizer.”
The product contains venlafaxine hydrochloride as the active substance. For approved indications please see the Summary of Product Characteristics.
Since this product has been shown to be essentially similar and refers to a product approved based on a full application with regard to preclinical data, no further such data has been submitted or is considered necessary.
Our company mission is to provide high quality, sustained release medicines which save money and where possible, provide improved benefits for patients.
Ethypharm UK Ltd will guarantee that the price of Venlalic® XL Tablets will not increase until April 2019 when the next PPRS agreement is scheduled to be agreed and signed.